Table 1.
Type and cycle of neoadjuvant chemotherapy.
| Characteristic | All | Squamous | Non-Squamous | P-Value |
|---|---|---|---|---|
| Number | n = 684 | n = 511 | n = 173 | |
| Regimen | <0.001 | |||
| Irinotecan based | 223 (32.6%) | 204 (39.9%) | 19 (11.0%) | |
| Taxane/platinum | 199 (29.1%) | 106 (20.7%) | 93 (53.8%) | |
| Mitomycin based | 91 (13.3%) | 80 (15.7%) | 11 (6.4%) | |
| Fluorouracil based | 71 (10.4%) | 52 (10.2%) | 19 (11.0%) | |
| Platinum monotherapy | 45 (6.6%) | 36 (7.0%) | 9 (5.2%) | |
| Ifosfamide based | 26 (3.8%) | 21 (4.1%) | 5 (2.9%) | |
| Others | 29 (4.2%) | 12 (2.3%) | 17 (9.8%) | |
| Cycles | 0.16 | |||
| 1 | 195 (28.5%) | 144 (28.2%) | 51 (29.5%) | |
| 2 | 382 (55.8%) | 295 (57.7%) | 87 (50.3%) | |
| 3 | 84 (12.3%) | 55 (10.8%) | 29 (16.8%) | |
| ≥4 | 23 (3.3%) | 17 (3.3%) | 6 (3.5%) |
Chi-square test for P-values. Significant P-values are emboldened.